Clinical Trials in San Antonio

Showing 2421-2440 of 7,028 trials

Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens

NCT05219669

This study is to compare the pharmacokinetics (how the body absorbs, breaks down and eliminates drug from your body) of nalmefene when given as a single dose intranasally (IN;into the nose), as a single dose in each nostril and as two doses in one nostrils; and to evaluate the safety and tolerability of nalmefene IN.

Opioid Overdose

Opiant Pharmaceuticals Inc24 participantsStarted Sep 2021

San Antonio, Texas, United States

COMPLETEDPhase 1< 1 mile

Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

NCT00881166

Adult subjects with malignant disease appropriate for treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel or erlotinib according to the standard dosing regimen will be enrolled in each treatment arm. Primary objective: Determine the MTD. Secondary objectives: Response rates, PK, quantify MP-470 on PK of SOC, and collect pharmacodynamic information. Evaluate the overall safety of MP-470 when co-administered with specific SOC treatments.

Malignant Disease

Astex Pharmaceuticals, Inc.101 participantsStarted Nov 2007

Scottsdale, Arizona, United States • Santa Monica, California, United States • San Antonio, Texas, United States +2 more locations

Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens

Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

Find Trials by Condition in San Antonio

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer

A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.

Effects Compressive Tissue Flossing on Lateral Elbow Tendinopathy in US Service Members

ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

A Study of ZN-c5 in Subjects With Breast Cancer

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Episealer® Knee System IDE Clinical Study

The clonoSEQ® Watch Registry

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)